Fox Chase Cancer Center News

PHILADELPHIA (July 8, 2021) — Mechanical removal is safer than more traditional methods of burning or ablating tumors that arise from recurrent respiratory papillomatosis (RRP), a respiratory disease caused by the human papilloma virus, according to the findings of a case series published recently by researchers at Fox Chase Cancer Center.

PHILADELPHIA (July 7, 2021) - Sanjeevani Arora, PhD, assistant professor in the Cancer Prevention and Control Program at Fox Chase Cancer Center, has received the Yale Head and Neck Specialized Program of Research Excellence (SPORE) Career Enhancement Program (CEP) Award. Arora will receive a one-year grant of $50,000 and eligibility for a second year of funding.

PHILADELPHIA (July 7, 2021) - Researchers at Fox Chase Cancer Center have been awarded a $50,000 research grant from the MANNA Institute to measure the impact of a medically tailored meal program in patients with a non-terminal cancer diagnosis.

PHILADELPHIA (July 1, 2021) - Fox Chase Cancer Center is pleased to announce the hiring of Marcus Messmer, MD, who will join the Department of Hematology/Oncology as an assistant professor.

PHILADELPHIA (June 30, 2021) – Fox Chase Cancer Center is pleased to announce the hiring of Peter Abdelmessieh, DO, MSc, who will join the Department of Bone Marrow Transplant and Cellular Therapies.

PHILADELPHIA (June 28, 2021) – A Fox Chase Cancer Center researcher has received a grant of approximately half a million dollars from the National Institutes of Health (NIH) to identify disease-causing T cell defects. The work will also involve developing genome editing as an improved and more personalized form of treatment of immune-related diseases.

PHILADELPHIA (June 22, 2021)—A new study by researchers at Fox Chase Cancer Center found that patients with muscle-invasive bladder cancer can safely receive chemotherapy, even when their tumors are blocking their kidneys. The findings mean that patients with the most serious form of this common cancer can receive potentially life-extending treatment, usually without the need for additional invasive procedures.

PHILADELPHIA (June 21, 2021)—Researchers at Fox Chase Cancer Center have identified Musashi-2 (MSI2) protein as having the potential to both identify targeted therapies for certain patients with non-small cell lung cancer (NSCLC) and to serve as a target for the development of new therapies.